Clinical Trials News

Tebipenem HBr Shows Promise as First Oral Carbapenem for Complicated Urinary Tract Infections

GSK - GlaxoSmithKline

Positive data from GSK’s pivotal PIVOT-PO Phase III trial show that oral tebipenem HBr is a promising new treatment for complicated urinary tract infections (cUTIs), including pyelonephritis. The study, which was stopped early for efficacy, demonstrated that the oral antibiotic was non-inferior to the current standard of care, intravenous imipenem-cilastatin. These findings mark a significant step towards the first oral carbapenem for cUTIs, potentially changing the treatment landscape for patients and addressing the challenge of antimicrobial resistance.

Regulatory Approval Autoimmune Diseases News

Roche’s Gazyva/Gazyvaro Gets U.S. FDA Approval for Lupus Nephritis Treatment

Roche

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva/Gazyvaro (obinutuzumab) for the treatment of adult patients with active lupus nephritis. Based on positive results from Phase II and III clinical trials, this new therapy offers a significant advancement for those suffering from this severe kidney complication of lupus, showing superiority over standard therapy alone.

Clinical Trials News Oncology

Gilead’s Trodelvy Shows Significant Promise in Treating Aggressive Breast Cancer

Gilead

Results from the ASCENT-03 study reveal that Trodelvy (sacituzumab govitecan-hziy) significantly enhances outcomes for patients with metastatic triple-negative breast cancer. The drug lowered the risk of disease progression or death by 38% and provided a longer duration of response compared to chemotherapy. This positions Trodelvy as a potential new standard of care for this aggressive form of breast cancer, offering hope to a patient population with limited treatment options.

Clinical Trials News Oncology

Breakthrough in Bladder Cancer Treatment: PADCEV and KEYTRUDA Combination Significantly Improves Survival

pfizer news

A landmark clinical trial reveals a powerful new weapon against aggressive bladder cancer. The combination of PADCEV™ and KEYTRUDA®, administered before and after surgery, has been shown to significantly improve survival rates for patients with muscle-invasive bladder cancer who are ineligible for cisplatin chemotherapy. These groundbreaking results could establish a new standard of care, offering profound hope for a patient population with previously limited options.

Clinical Trials News Oncology

Lilly’s Verzenio® Shows Significant Survival Benefit in High-Risk Early Breast Cancer

Eli Lilly and Company

Eli Lilly and Company announced major findings from the seven-year monarchE trial. Their CDK4/6 inhibitor, Verzenio® (abemaciclib), is the first in its class to demonstrate a statistically significant overall survival benefit for patients with HR+, HER2-, high-risk early breast cancer when added to endocrine therapy.

Clinical Trials News Weight-loss Drugs

Lilly’s Orforglipron, a New Oral Drug, Shows Promise for Type 2 Diabetes and Weight Loss in Late-Stage Trials

Eli Lilly and Company

Eli Lilly has announced positive late-stage trial results for orforglipron, its investigational once-daily oral GLP-1 drug. In Phase 3 studies, orforglipron demonstrated superior blood sugar control and significant weight loss in adults with type 2 diabetes, outperforming other existing medications. These results position it as a potential new standard of care and a convenient oral alternative to injectable treatments.

Business Healthcare & Pharmaceuticals News

Johnson & Johnson Raises 2025 Sales Outlook on Strong Q3 Performance

JohnsonAndJohnson

Johnson & Johnson announced strong third-quarter 2025 financial results, with reported sales increasing by 6.8% to $24.0 billion. The company’s Innovative Medicine and MedTech divisions both contributed to this growth. As a result of this strong performance, Johnson & Johnson has raised its full-year 2025 sales guidance.

Oncology News

ESMO 2025 Preview: Roche, Lilly, AbbVie, and Gilead to Present Latest Oncology Data

ESMO_2025

Leading pharmaceutical companies including Roche, Eli Lilly, AbbVie, and Gilead/Kite are set to present significant new data from their oncology pipelines at the ESMO Congress 2025 in Berlin (Oct 17-21). Presentations will highlight advancements in targeted therapies, ADCs, and cell therapy for multiple cancer types, focusing on key drugs like Tecentriq, Verzenio, and Trodelvy.

Business News

AstraZeneca Strikes ‘Historic’ Drug Pricing Deal with US Government, Commits $50 Billion to US Manufacturing

AstraZeneca

AstraZeneca has announced a landmark agreement with the US government to significantly cut the cost of prescription medicines for millions of American patients via the Most-Favored-Nation (MFN) drug pricing model. The deal includes up to 98% discounts on key respiratory drugs for direct patient purchases and a $50 billion commitment to US manufacturing and R&D, securing a three-year exemption from threatened tariffs.